We have a few small clinical stage firms in the Prohost Portfolio that were established with the goal of designing safer and more effective versions of the very promising CAR T immuno-oncology products. We intend to revisit these firms and see how far they have reached on what can be described as a very hard road towards the realization of these small ambitious firms’ goals. Among these firms we have: Bellicum Pharmaceuticals (BLCM) and Celyad (CYAD). These firms created their own technologies to improve on the safety and efficacy . . .